Biomaxima
BioMaxima S.A. produces and distributes microbiological media, reagents, and in vitro diagnostic equipment in Poland. It offers microbiology products, including ready to use media, such as plates, bottles, bags, and media in tubes; dehydrated media; agars and peptones; and supplements. The company also provides molecular biology and cell culture products which includes real time PCR, nucleic acid… Read more
Biomaxima (BMX) - Total Assets
Latest total assets as of September 2025: zł77.32 Million PLN
Based on the latest financial reports, Biomaxima (BMX) holds total assets worth zł77.32 Million PLN as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Biomaxima - Total Assets Trend (2009–2024)
This chart illustrates how Biomaxima’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Biomaxima - Asset Composition Analysis
Current Asset Composition (December 2024)
Biomaxima's total assets of zł77.32 Million consist of 33.3% current assets and 66.7% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 1.2% |
| Accounts Receivable | zł11.01 Million | 14.4% |
| Inventory | zł13.52 Million | 17.7% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł318.00K | 0.4% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2009–2024)
This chart illustrates how Biomaxima's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomaxima's current assets represent 33.3% of total assets in 2024, a decrease from 66.7% in 2009.
- Cash Position: Cash and equivalents constituted 1.2% of total assets in 2024, up from 0.9% in 2009.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2009.
- Asset Diversification: The largest asset category is inventory at 17.7% of total assets.
Biomaxima Competitors by Total Assets
Key competitors of Biomaxima based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ADCNF
OTCGREY:ADCNF
|
USA | $4.51 Billion |
|
Berry Genomics Co Ltd
SHE:000710
|
China | CN¥2.34 Billion |
|
Malaysian Genomics Resource
KLSE:0155
|
Malaysia | RM20.70 Million |
|
NSN Co. Ltd
KQ:031860
|
Korea | ₩60.96 Billion |
|
JOONGANG DNM Co.Ltd
KQ:051980
|
Korea | ₩121.79 Billion |
|
GeneMatrix Inc
KQ:109820
|
Korea | ₩28.03 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩125.67 Billion |
|
Green Cross Lab Cell Corporation
KQ:144510
|
Korea | ₩565.79 Billion |
Biomaxima - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Moderate asset utilization - Biomaxima generates 0.69x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Moderate ROA - For every $100 in assets, Biomaxima generates $ 0.70 in net profit.
Biomaxima - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.41 | 1.56 | 2.19 |
| Quick Ratio | 0.71 | 0.68 | 0.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł7.95 Million | zł 8.73 Million | zł 15.10 Million |
Biomaxima - Advanced Valuation Insights
This section examines the relationship between Biomaxima's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.15 |
| Latest Market Cap to Assets Ratio | 0.10 |
| Asset Growth Rate (YoY) | 3.5% |
| Total Assets | zł76.34 Million |
| Market Capitalization | $7.70 Million USD |
Valuation Analysis
Below Book Valuation: The market values Biomaxima's assets below their book value (0.10 x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Biomaxima's assets grew by 3.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Biomaxima (2009–2024)
The table below shows the annual total assets of Biomaxima from 2009 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł76.34 Million | +3.46% |
| 2023-12-31 | zł73.78 Million | -0.86% |
| 2022-12-31 | zł74.42 Million | +20.17% |
| 2021-12-31 | zł61.93 Million | +15.90% |
| 2020-12-31 | zł53.43 Million | +23.41% |
| 2019-12-31 | zł43.30 Million | -1.52% |
| 2018-12-31 | zł43.96 Million | +61.01% |
| 2017-12-31 | zł27.30 Million | +16.61% |
| 2016-12-31 | zł23.42 Million | +6.61% |
| 2015-12-31 | zł21.96 Million | +2.55% |
| 2014-12-31 | zł21.42 Million | -5.22% |
| 2013-12-31 | zł22.60 Million | +16.05% |
| 2012-12-31 | zł19.47 Million | +48.39% |
| 2011-12-31 | zł13.12 Million | +24.97% |
| 2010-12-31 | zł10.50 Million | +82.99% |
| 2009-12-31 | zł5.74 Million | -- |